FGF23 and osteoporosis: Chronic inflammation status, parathyroid hormone abnormalities, and elevating circulating levels of fibroblast growth factor 23 (FGF23) could affect normal osteoblast function in chronic kidney disease stage 5D (CKD stage 5D) patients, resulting in osteoporosis [1].